Anti-necroptotic effects of human Wharton’s jelly-derived mesenchymal stem cells in skeletal muscle cell death model via secretion of GRO-α
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0313693 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Sang Eon Park und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cell and Gene Therapy Institute, ENCell Co. Ltd, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Wharton Jelly, Necroptosis, Muscle, Skeletal. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Health Industry Development Institute, National Research Foundation of Korea, Ministry of Science and ICT, South Korea.
Abstract (Originalsprache)
Human mesenchymal stem cells (hMSCs) have therapeutic applications and potential for use in regenerative medicine. However, the use of hMSCs in research and clinical medicine is limited by a lack of information pertaining to their donor-specific functional attributes. In this study, we compared the characteristics of same-donor derived placenta (PL) and Wharton’s jelly (WJ)-derived hMSCs, we also compared their mechanism of action in a skeletal muscle disease in vitro model. The same-donor-derived hWJ- and hPL-MSCs exhibited typical hMSC characteristics. However, GRO-α was differentially expressed in hWJ- and hPL-MSCs. hWJ-MSCs, which secreted a high amount of GRO-α, displayed a higher ability to inhibit necroptosis in skeletal muscle cells than hPL-MSCs. This demonstrates the anti-necroptotic therapeutic effect of GRO-α in the skeletal muscle cell death model. Furthermore, GRO-α also exhibited the anti-necroptotic effect in a Duchenne muscular dystrophy (DMD) mouse model. Considering their potential to inhibit necroptosis in skeletal muscle cells, hWJ-MSCs and the derived GRO-α are novel treatment options for skeletal muscle diseases such as DMD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Cell and Gene Therapy Institute, ENCell Co. Ltd, Seoul, Republic of Korea.
- Cell and Gene Therapy Institute, Samsung Medical Center, Seoul, Republic of Korea.
- Department of Obstetrics and Gynecology, Samsung Medical Center, Seoul, Republic of Korea.
- Department of Medical Device Management and Research, Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
- The Office of R&D Strategy & Planning, Samsung Medical Center, Seoul, Republic of Korea.
- Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University, Seoul, Korea.
ORCID-Profile: Hong Bae Jeon
Förderung
- Korea Health Industry Development Institute
- National Research Foundation of Korea
- Ministry of Science and ICT, South Korea
- Samsung Medical Center, south korea
Zitieren
APA
Park, S. E., Kwon, S. J., Kim, S. J., Jeong, J. B., Kim, M. J., Choi, S. J., Oh, S. Y., Ryu, G. H., Jeon, H. B., & Chang, J. W. (2024). Anti-necroptotic effects of human Wharton’s jelly-derived mesenchymal stem cells in skeletal muscle cell death model via secretion of GRO-α. PLOS ONE. https://doi.org/10.1371/journal.pone.0313693
Vancouver
Park SE, Kwon SJ, Kim SJ, Jeong JB, Kim MJ, Choi SJ, et al. Anti-necroptotic effects of human Wharton’s jelly-derived mesenchymal stem cells in skeletal muscle cell death model via secretion of GRO-α. PLOS ONE. 2024. doi:10.1371/journal.pone.0313693
BibTeX
@article{Park2024,
author = {Park, Sang Eon and Kwon, Soo Jin and Kim, Sun Jeong and Jeong, Jang Bin and Kim, Min-Jeong and Choi, Suk-Joo and Oh, Soo-Young and Ryu, Gyu Ha and Jeon, Hong Bae and Chang, Jong Wook},
title = {Anti-necroptotic effects of human Wharton’s jelly-derived mesenchymal stem cells in skeletal muscle cell death model via secretion of GRO-α},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0313693}
}
EUVIMED